Last reviewed · How we verify
Custodiol Htk Soln
Custodiol HTK is an organ preservation solution that maintains cellular viability during cold storage by providing essential electrolytes, buffers, and metabolic substrates while minimizing ischemic injury.
Custodiol HTK is an organ preservation solution that maintains cellular viability during cold storage by providing essential electrolytes, buffers, and metabolic substrates while minimizing ischemic injury. Used for Cold preservation of donor organs (heart, kidney, liver, pancreas) for transplantation.
At a glance
| Generic name | Custodiol Htk Soln |
|---|---|
| Also known as | Custodiol HTK solution. ACT: K944866 |
| Sponsor | Lourdes Montero Cruces |
| Drug class | Organ preservation solution |
| Modality | Small molecule |
| Therapeutic area | Transplantation |
| Phase | FDA-approved |
Mechanism of action
Custodiol HTK (histidine-tryptophan-ketoglutarate solution) is a specialized extracellular-type preservation fluid designed for hypothermic organ storage. It contains a balanced composition of electrolytes, amino acids (histidine and tryptophan), and ketoglutarate that reduces intracellular edema, maintains cellular metabolism, and protects against reperfusion injury during the cold ischemic period before organ transplantation.
Approved indications
- Cold preservation of donor organs (heart, kidney, liver, pancreas) for transplantation
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Custodiol Htk Soln CI brief — competitive landscape report
- Custodiol Htk Soln updates RSS · CI watch RSS
- Lourdes Montero Cruces portfolio CI